400 related articles for article (PubMed ID: 19234505)
1. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
[No Abstract] [Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation as treatment for myelofibrosis.
Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
[TBL] [Abstract][Full Text] [Related]
4. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
5. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
6. Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis.
Kiss TL; Messner HA; Galal A; Lipton J
Bone Marrow Transplant; 2005 Jan; 35(2):213-4. PubMed ID: 15531899
[No Abstract] [Full Text] [Related]
7. A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis.
George B; Kerridge I; Gottlieb D; Huang G; Hertzberg M; Svennilson J; Bradstock K
Bone Marrow Transplant; 2008 Oct; 42(8):567-8. PubMed ID: 18660841
[No Abstract] [Full Text] [Related]
8. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
[No Abstract] [Full Text] [Related]
9. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
Craddock CF
Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.
Verholen F; Terrettaz M; Roosnek E; Passweg JR; Chalandon Y
Eur J Haematol; 2009 Sep; 83(3):273-5. PubMed ID: 19500136
[No Abstract] [Full Text] [Related]
11. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Lekakis L; de Lima M
Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for ALL in adults.
Stein A; Forman SJ
Bone Marrow Transplant; 2008 Mar; 41(5):439-46. PubMed ID: 18334992
[TBL] [Abstract][Full Text] [Related]
13. Rapid full engraftment and successful immune reconstitution after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in Omenn syndrome.
Gozdzik J; Czogala W; Skoczen S; Krasowska-Kwiecien A; Wiecha O; Mordel A; Lesko E; Majka M; Kowalczyk D; Zembala M
Pediatr Transplant; 2009 Sep; 13(6):760-5. PubMed ID: 18992055
[TBL] [Abstract][Full Text] [Related]
14. Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.
Siragusa S; Passamonti F; Cervantes F; Tefferi A
Am J Hematol; 2009 Mar; 84(3):140-3. PubMed ID: 19123461
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation.
Kruspe RC; Ashraf KK; Foran JM; Salzman DE; Reddy VV; Vaughan WP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):882-4; discussion 884. PubMed ID: 18185486
[No Abstract] [Full Text] [Related]
16. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
[TBL] [Abstract][Full Text] [Related]
17. [Non-myeloablative allogeneic hematopoietic stem cell transplantation for treatment of high-risk idiopathic myelofibrosis: a case report and literature review].
Yang J; Wang C; Cai Y
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):129-31. PubMed ID: 21429385
[No Abstract] [Full Text] [Related]
18. Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
Fleischman AG; Maziarz RT
Curr Opin Hematol; 2013 Mar; 20(2):130-6. PubMed ID: 23314844
[TBL] [Abstract][Full Text] [Related]
19. [Stem cell transplantation in myelofibrosis].
Toivari A; Itälä-Remes M; Kauppila M; Putkonen M; Salmenniemi U; Remes K
Duodecim; 2011; 127(22):2375-82. PubMed ID: 22238916
[TBL] [Abstract][Full Text] [Related]
20. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
